Literature DB >> 22459148

MicroRNA-224 is up-regulated in hepatocellular carcinoma through epigenetic mechanisms.

Yu Wang1, Han Chong Toh, Pierce Chow, Alexander Y F Chung, David J Meyers, Philip A Cole, London L P J Ooi, Caroline G L Lee.   

Abstract

MicroRNA-224 (miR-224) is one of the most commonly up-regulated microRNAs in hepatocellular carcinoma (HCC), which affects crucial cellular processes such as apoptosis and cell proliferation. In this study, we aim to elucidate the molecular mechanism that leads to the overexpression of miR-224 in HCC. We examined the transcript expression of miR-224 and neighboring miR-452 and genes on chromosome Xq28 in tumor and paired adjacent nontumorous tissues from 100 patients with HCC and found that miR-224 is coordinately up-regulated with its neighboring microRNA (miRNA) and genes. This coordinated up-regulation of miRNAs and genes at the Xq28 locus can be mimicked in nontransformed immortalized human liver cells by the introduction of histone deacetylase (HDAC) inhibitors, which resulted in a corresponding increase in histone H3 acetylation in this region. This miR-224-residing locus in Xq28 is reciprocally regulated by HDAC1, HDAC3, and histone acetylase protein, E1A binding protein p300 (EP300). Notably, in HCC tumors that significantly overexpress microRNA-224, EP300 is also overexpressed and displays increased binding to the Xq28 locus. In transformed HCC cells, high miR-224 expression can be attenuated through the inhibition of EP300, using either siRNA or the specific drug C646. In summary, overexpression of EP300 may account, in part, for the up-regulation of miR-224 expression in patients with HCC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22459148      PMCID: PMC3382089          DOI: 10.1096/fj.11-201855

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  31 in total

1.  Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor.

Authors:  Erin M Bowers; Gai Yan; Chandrani Mukherjee; Andrew Orry; Ling Wang; Marc A Holbert; Nicholas T Crump; Catherine A Hazzalin; Glen Liszczak; Hua Yuan; Cecilia Larocca; S Adrian Saldanha; Ruben Abagyan; Yan Sun; David J Meyers; Ronen Marmorstein; Louis C Mahadevan; Rhoda M Alani; Philip A Cole
Journal:  Chem Biol       Date:  2010-05-28

2.  Lethal-7 is down-regulated by the hepatitis B virus x protein and targets signal transducer and activator of transcription 3.

Authors:  Yu Wang; Yiwei Lu; Soo Ting Toh; Wing-Kin Sung; Patrick Tan; Pierce Chow; Alexander Y F Chung; London L P Jooi; Caroline G L Lee
Journal:  J Hepatol       Date:  2010-04-02       Impact factor: 25.083

3.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

Review 4.  Role of miR-224 in hepatocellular carcinoma: a tool for possible therapeutic intervention?

Authors:  Yu Wang; Caroline G L Lee
Journal:  Epigenomics       Date:  2011-04       Impact factor: 4.778

5.  Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma.

Authors:  Shunsuke Ura; Masao Honda; Taro Yamashita; Teruyuki Ueda; Hajime Takatori; Ryuhei Nishino; Hajime Sunakozaka; Yoshio Sakai; Katsuhisa Horimoto; Shuichi Kaneko
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

6.  Core promoter structure and genomic context reflect histone 3 lysine 9 acetylation patterns.

Authors:  Anton Kratz; Erik Arner; Rintaro Saito; Atsutaka Kubosaki; Jun Kawai; Harukazu Suzuki; Piero Carninci; Takahiro Arakawa; Masaru Tomita; Yoshihide Hayashizaki; Carsten O Daub
Journal:  BMC Genomics       Date:  2010-04-21       Impact factor: 3.969

7.  Regulation of miRNA expression by Src and contact normalization: effects on nonanchored cell growth and migration.

Authors:  X Li; Y Shen; H Ichikawa; T Antes; G S Goldberg
Journal:  Oncogene       Date:  2009-09-21       Impact factor: 9.867

8.  Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype.

Authors:  Erin Connolly; Margherita Melegari; Pablo Landgraf; Tatyana Tchaikovskaya; Bud C Tennant; Betty L Slagle; Leslie E Rogler; Mihaela Zavolan; Thomas Tuschl; Charles E Rogler
Journal:  Am J Pathol       Date:  2008-08-07       Impact factor: 4.307

9.  Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma.

Authors:  Laura Gramantieri; Manuela Ferracin; Francesca Fornari; Angelo Veronese; Silvia Sabbioni; Chang-Gong Liu; George A Calin; Catia Giovannini; Eros Ferrazzi; Gian Luca Grazi; Carlo M Croce; Luigi Bolondi; Massimo Negrini
Journal:  Cancer Res       Date:  2007-07-01       Impact factor: 12.701

10.  Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival.

Authors:  Jinmai Jiang; Yuriy Gusev; Ileana Aderca; Teresa A Mettler; David M Nagorney; Daniel J Brackett; Lewis R Roberts; Thomas D Schmittgen
Journal:  Clin Cancer Res       Date:  2008-01-15       Impact factor: 12.531

View more
  56 in total

1.  Function and clinical potential of microRNAs in hepatocellular carcinoma.

Authors:  Lijuan Wang; Yongfang Yue; Xian Wang; Hongchuan Jin
Journal:  Oncol Lett       Date:  2015-09-29       Impact factor: 2.967

2.  Down-regulation of miR-452 is associated with poor prognosis in the non-small-cell lung cancer.

Authors:  Zhicheng He; Yang Xia; Bin Liu; Xiaotong Qi; Zhi Li; Jun Wang; Liang Chen; Yijiang Chen
Journal:  J Thorac Dis       Date:  2016-05       Impact factor: 2.895

3.  Identification of differentially expressed microRNAs in human hepatocellular adenoma associated with type I glycogen storage disease: a potential utility as biomarkers.

Authors:  Li-Ya Chiu; Priya S Kishnani; Tzu-Po Chuang; Cheng-Yang Tang; Cheng-Yuan Liu; Deeksha Bali; Dwight Koeberl; Stephanie Austin; Keri Boyette; David A Weinstein; Elaine Murphy; Adam Yao; Yuan-Tsong Chen; Ling-Hui Li
Journal:  J Gastroenterol       Date:  2013-10-16       Impact factor: 7.527

Review 4.  Protein lysine acetylation by p300/CBP.

Authors:  Beverley M Dancy; Philip A Cole
Journal:  Chem Rev       Date:  2015-01-16       Impact factor: 60.622

5.  E2F1 induces miR-224/452 expression to drive EMT through TXNIP downregulation.

Authors:  Susanne Knoll; Katharina Fürst; Bhavani Kowtharapu; Ulf Schmitz; Stephan Marquardt; Olaf Wolkenhauer; Hubert Martin; Brigitte M Pützer
Journal:  EMBO Rep       Date:  2014-10-23       Impact factor: 8.807

6.  Identification of microRNAs specifically expressed in hepatitis C virus-associated hepatocellular carcinoma.

Authors:  Giacomo Diaz; Marta Melis; Ashley Tice; David E Kleiner; Lopa Mishra; Fausto Zamboni; Patrizia Farci
Journal:  Int J Cancer       Date:  2013-03-16       Impact factor: 7.396

7.  SRC points the way to biomarkers and chemotherapeutic targets.

Authors:  Harini Krishnan; W Todd Miller; Gary S Goldberg
Journal:  Genes Cancer       Date:  2012-05

Review 8.  MicroRNA-224: as a potential target for miR-based therapy of cancer.

Authors:  Wei Chen; Xue-Mei Fan; Ling Mao; Jun-Ying Zhang; Jian Li; Jian-Zhong Wu; Jin-Hai Tang
Journal:  Tumour Biol       Date:  2015-08-08

9.  Identification of circulating microRNAs in HNF1A-MODY carriers.

Authors:  C Bonner; K C Nyhan; S Bacon; M P Kyithar; J Schmid; C G Concannon; I M Bray; R L Stallings; J H M Prehn; M M Byrne
Journal:  Diabetologia       Date:  2013-05-15       Impact factor: 10.122

10.  Live-cell studies of p300/CBP histone acetyltransferase activity and inhibition.

Authors:  Beverley M Dancy; Nicholas T Crump; Daniel J Peterson; Chandrani Mukherjee; Erin M Bowers; Young-Hoon Ahn; Minoru Yoshida; Jin Zhang; Louis C Mahadevan; David J Meyers; Jef D Boeke; Philip A Cole
Journal:  Chembiochem       Date:  2012-09-07       Impact factor: 3.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.